Protara Therapeutics, Inc.
TARA
$3.11
$0.010.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.88% | 3.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.43% | -1.31% | |||
| Operating Income | -17.43% | 1.31% | |||
| Income Before Tax | -25.57% | 6.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.57% | 6.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.57% | 6.70% | |||
| EBIT | -17.43% | 1.31% | |||
| EBITDA | -17.43% | 1.33% | |||
| EPS Basic | -20.91% | 39.41% | |||
| Normalized Basic EPS | -20.94% | 39.42% | |||
| EPS Diluted | -20.91% | 39.41% | |||
| Normalized Diluted EPS | -20.94% | 39.42% | |||
| Average Basic Shares Outstanding | 3.84% | 54.01% | |||
| Average Diluted Shares Outstanding | 3.84% | 54.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||